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Introduction
Iron overload is a common clinical problem, 
arising from disorders of increased iron absorption 
such as hereditary haemochromatosis or thalassaemia 
intermedia syndromes or as a consequence of chronic 
blood transfusions for various blood disorders. 
Regular red blood cell (RBC) transfusions are the 
principal supportive therapy for many rare anaemias 
involving a decrease in RBC production, an increase 
in cell destruction, or chronic blood loss1. Anaemias 
such as beta-thalassaemia and sickle cell disease are 
examples of chronic diseases that require long-term 
transfusion therapy to improve life expectancy.
Although transfusion requirements may vary 
according to the diagnosis, chronic blood transfusion 
therapy inevitably leads to secondary iron overload 
that can cause significant damage to many organs, such 
as the liver and heart, and to the endocrine system2,3. 
Iron overload is associated with the production of free 
radicals that can damage tissues, resulting in cardiac 
toxicity, endocrine dysfunction, and liver toxicity. 
The effects of iron overload are visible after damage 
has been done, when patients already have liver 
dysfunction, cirrhosis, cardiomyopathy or diabetes1,4. 
Iron is an essential element within the body and 
its quantity is tightly regulated physiologically; 
however, the body has no mechanism to excrete 
excess iron and it deposits iron into end organs 
leading to severe dysfunction. Each unit of RBC 
transfused contains 180 to 200 mg of iron. Chronic 
packed RBC transfusion therapy increases liver 
iron by approximately 1 mg/mL (by dry weight) 
for every 15 mL/kg delivered5. Labile plasma iron 
(LPI) is a toxic and chelatable form of iron that 
is produced continually during conditions of iron 
overload, and has been linked to the development 
of co-morbidities6. It is very important to remove 
excess iron and suppress LPI to avoid the serious 
clinical sequelae associated with iron overload. In this 
specific context phlebotomy cannot be used because 
patients are usually anaemic and other means must be 
used to mobilise the excess iron. The gold standard 
is iron chelation therapy.
Methods for evaluating iron overload
There are various different methods for evaluating 
the degree of iron overload, including serum ferritin 
levels, liver iron concentration determined from 
a biopsy, superconducting quantum interference 
device (SQUID) and magnetic resonance imaging 
(MRI). Each method has pros and cons, and often 
a combination of these tests is used to quantify and 
monitor iron burden.
The simplest way to quantify iron overload is to 
count the number of RBC units that a patient has 
been transfused over time7. Another simple method 
of evaluation is to test serum ferritin levels, which 
correlate with body iron stores. Although trends 
in serum ferritin remain an important monitoring 
tool, serum ferritin is a poor marker of iron balance 
because ferritin values can change in the presence 
of inflammation/infection, or ascorbate deficiency, 
and according to the intensity of blood transfusion 
therapy, making the reliability of ferritin levels 
questionable8. 
The gold standard for assessing the degree of 
iron overload is a liver biopsy, but its invasiveness 
limits is use for routine screening at most institutions. 
Liver iron concentration >15 mg/g dry weight 
predicts a higher risk of cardiac disease and death9 
and progression of hepatic fibrosis, which may be 
exacerbated by hepatitis C infection, a very common 
condition in patients transfused before the 1980s10,11.
MRI is a non-invasive method which can quantify 
hepatic and cardiac iron, replacing liver biopsy for 
quantification of iron in the liver12. The ability of 
MRI to quantify extra-hepatic iron has had a great 
impact on patients' care and on our understanding of 
the pathophysiology of iron overload. In particular, 
cardiac iron can be investigated in asymptomatic 
patients by cardiac T2*, and signal changes shown 
by MRI could be used as pre-clinical end-points for 
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evaluating response to chelation13. Therefore, after 
at least 10 transfusions (150 mL/kg), in the absence 
of significant losses, chronically transfused patients 
merit at least an initial MRI scan. In addition, patients 
with a high transfusion load, an unknown transfusion 
burden, or with Diamond-Blackfan syndrome (in 
which cardiac iron loading is exhibited early14) may 
warrant cardiac examination at their initial evaluation.
Recently, MRI estimates of cardiac and liver 
iron have become the primary outcome measures 
for clinical studies on iron chelation therapy15-17. 
Cardiac complications remain the most common 
cause of death in transfused thalassaemia patients8 
and a central goal of iron chelation therapy is to 
prevent or remove cardiac iron loading. Cardiac 
T2* values of 10-20 ms indicate mild to moderate 
iron loading and values <10 ms indicate severe 
myocardial siderosis. In thalassaemia major, the 
risk of developing clinically relevant left ventricular 
dysfunction increases as the T2* falls below the lower 
limit found in healthy adults (approximately 20 ms). 
Patients with very low T2* values (<6 ms) have a 
47% chance of developing congestive heart failure 
within the following year18. Low cardiac T2* values 
(<20 ms) should, therefore, trigger intensification of 
chelation regimes regardless of liver iron burden. The 
development of cardiac dysfunction or arrhythmia 
should also prompt intensification of chelation 
therapy, for example considering the combination of 
different iron chelators (as described below).
Iron is removed from different organs at different 
rates: hepatic iron burden usually improves more 
rapidly than cardiac iron burden with intensification 
of chelation. For this reason both hepatic and cardiac 
iron must be measured to optimise the chelation 
therapy. Changes in ferritin levels often parallel 
changes in liver iron concentration, even if a variety of 
factors, such as inflammation, infection and ascorbate 
deficiency, can decrease or increase ferritin levels. 
According to this evidence, serial ferritin levels may 
be used to assess trends in iron burden and to help to 
modify chelator dosing. In particular, ferritin levels 
above 2,500 ng/mL are associated with an increased 
risk of morbidity and mortality, and levels persistently 
above this value should trigger intensification of the 
chelation regimen.
Future frontiers in MRI monitoring include 
improved prevention of endocrine toxicities, 
particularly hypogonadotropic hypogonadism and 
diabetes.
Iron chelation therapy
The overall aim of chelation therapy is to 
maintain a "safe" iron status at all times. Ideally, 
chelation therapy should be administered to prevent 
iron accumulation and iron-related complications 
including hepatic, endocrinological and cardiac 
dysfunction. There is evidence showing that the 
age at which iron chelation is started in patients 
with thalassaemia major is a key factor in their 
survival8,19,20, although this aspect is often not 
considered in retrospective analyses of survival data.
In practice, chelation therapy is often used to 
remove excess stored iron and to reverse related 
complications. Generally, chelation therapy with 
deferoxamine (DFO; see below) has traditionally 
been started only after 2 to 3 years of transfusion or 
when ferritin exceeds 1,000 ng/mL. Iron chelation 
therapy provides a viable method of treating 
iron overload and minimising the adverse effects 
associated with iron burden. The direct capture of 
non-transferrin bound iron and LPI with effective 
chelation therapy may help to prevent the adverse 
consequences of iron overload6. Several iron chelators 
have been developed, designed to mobilise tissue iron 
by forming complexes that are excreted in the faeces 
and/or urine (Table I).
Before the routine availability of chelation 
therapy, chronically transfused patients died from 
cardiac iron overload in their teens and twenties21. 
Since the introduction of deferoxamine (Desferal®; 
DFO; Novartis Pharma AG, Basel, Switzerland) in 
the early 1970s, the life expectancy of such patients 
has improved dramatically8. 
DFO was developed more than 40 years ago and 
the wealth of clinical experience in iron-overloaded 
patients has established a role for iron chelators in the 
improvement of patients' quality of life and overall 
survival22,23. Data indicate that DFO is effective at 
lowering serum ferritin levels and hepatic iron24,25 and 
in preventing endocrine complications19,26. Long-term 
therapy with DFO is also associated with a reduction 
in cardiac complications and improved survival8. In 
addition, doses of DFO higher than 60 mg/kg/day as 
a continuous intravenous infusion can reverse cardiac 
iron burden27 as measured by cardiac T2*28. 
411-422_008-12.indd   412 01/10/2012   10.17.37
413
Blood Transfus 2012; 10: 411-22  DOI 10.2450/2012.0008-12
Update on iron chelation therapy
Table I - Overview of iron chelators.
Property Deferoxamine Deferiprone Deferasirox
Stoichiometry
(chelator:iron)
Hexadentate (1:1) Bidentate (3:1) Tridentate (2:1)
Route Subcutaneous, intravenous Oral tablet or solution Tablets for oral suspension
Usual dose 20-40 mg/kg/day over 8-24 hours, 
5 days/week
75-100 mg/kg/day in 3 divided doses 
daily
Recommended initial dose 20 mg/kg 
up to a maximum of 40 mg/kg/day
Excretion Urinary, faecal Mainly urinary Faecal
Half-life 20-30 min 3-4 hours 8-16 hours
Adverse effects Local skin reactions 
Ophthalmological
Auditory 
Allergic reactions
Growth retardation
Bone abnormalities
Pulmonary at high doses
Neurological at high doses
Gastrointestinal Agranulocytosis/
neutropenia
Arthralgia
Elevated liver enzymes
Gastrointestinal
Rash
Rise in creatinine 
Proteinuria
Ophthalmological
Auditory
Elevated liver enzymes
Challenges Adherence due to parenteral 
administration; need for yearly 
ophthalmology and audiometric 
examination
Need for weekly blood count 
monitoring; not commercially 
available in all countries; limited 
data in children; variable efficacy in 
removal of hepatic iron
Cost, especially with higher doses; 
gastrointestinal side effects may limit 
optimal dosing
Need for monthly monitoring of 
creatinine, transaminases, bilirubin, 
complete blood count for potential 
renal or hepatic failure and/or 
gastrointestinal haemorrhage (more 
frequently in patients with advanced 
age and existing comorbidities)
Status Licensed Licensed in USA and Europe Licensed in USA and Europe
Indications Treatment of chronic iron overload 
due to transfusion-dependent 
anaemias (and for treatment of acute 
iron intoxication)
Treatment of iron overload in 
thalassemia major when DFO is 
contraindicated or inadequate.
In USA licensed for the treatment 
of chronic iron overload due to 
transfusion-dependent anaemias in 
individuals aged 2 years and older
In Europe licensed for the treatment 
of transfusional iron overload in beta-
thalassaemia major patients, 6 years 
and older, and approved for use when 
DFO is inadequate or contraindicated 
in patients with other anaemias, 
patients 2-5 years, and patients 
with non-transfusion-dependent 
thalassaemia
Age considerations Not recommended for children <3 
years with low transfusional burden
Limited or no data on children aged 
<6-10 years
Studied in children as young as 
2 years old
DFO is a hexadentate chelator binding iron at a 
1:1 molar ratio, thus preventing its participation in 
toxic reactions. In accordance with its relatively high 
molecular weight and highly hydrophilic properties, 
DFO does not readily enter most types of cells, with 
the exception of hepatocytes, which seem to have a 
facilitated uptake mechanism29. The iron complex 
of DFO is highly stable, with good iron-scavenging 
properties at low concentrations of iron or chelator. 
The most common adverse effects of DFO are 
listed in Table I. Redness and induration at the 
infusion site are the most frequent. Ophthalmological, 
auditory and bone toxicity and growth retardation can 
be minimised by avoiding "over-chelation".
The greatest challenge with DFO is patients' 
adherence to therapy. Due to its poor oral 
bioavailability and short plasma half-life, DFO 
must be given by slow subcutaneous administration 
over 8-12 hours, 5-7 days/week, often resulting in 
poor compliance30. DFO infusions frequently have 
a negative impact on patients' quality of life, as the 
infusions can be troublesome, time-consuming and 
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painful. A review of published data suggests that 
compliance with DFO is between approximately 60% 
and 80%31. Poor compliance leads to gaps in chelation 
coverage, during which LPI levels can increase and 
cause further tissue damage. Morbidity and mortality 
in thalassaemia are closely linked to the adequacy of 
chelation. Cardiac morbidity and mortality continue 
to occur in patients treated with DFO, probably 
related to difficulties with adherence32.
The burden of this demanding regimen and the 
poor compliance led to the search for more convenient 
oral chelators. There are currently two oral iron 
chelators licensed for the treatment of iron overload.
Deferiprone (Ferriprox®; DFP; Apotex Inc., 
Toronto, ON, Canada), first tested in clinical trials 
in the 1980s, is available in the European Union 
and Canada, and recently the U.S. Food and Drug 
Administration approved deferiprone for the treatment 
of iron overload due to blood transfusions in patients 
with thalassaemia, who had an inadequate response to 
prior chelation therapy (European Medicine Agency. 
http://www.ferriprox.com; U.S. Food and Drug 
Administration http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/ucm275814.htm).
DFP is a small lipophilic molecule, which binds to 
iron in a 3:1 ratio and can enter myocytes and capture 
LPI in specific organelles of cardiomyocytes and 
macrophages. DFP facilitates transfer of iron from 
extracellular media into nuclei and mitochondria, 
from endosomes to nuclei, and from intracellular 
compartments to extracellular apotransferrin. 
Furthermore, it mobilises iron from iron-loaded cells 
and donates it to pre-erythroid cells for haemoglobin 
synthesis, both in the presence and in the absence 
of transferrin. These unique properties of DFP 
mechanistically underlie its capacity to alleviate 
iron accumulation in several conditions, including 
neurodegeneration with brain iron accumulation, 
such as Friedreich's ataxia33,34, and to donate tissue-
chelated iron to plasma transferrin in patients with 
thalassaemia intermedia35.
DFP has a short half-life (3-4 hours) and must, 
therefore, be given three times daily. DFP is often used 
in combination with DFO; in this case, treatment can 
be sequential (both chelators are given in any 24-hour 
period) or alternating (only one chelator is administered 
in any 24-hour period). Adherence is likely to depend 
on the regimen used: a regimen that reduces the number 
of days of DFO therapy (e.g. alternating therapy) may 
improve adherence, while a regimen using the standard 
DFO treatment plus DFP (e.g. sequential therapy) may 
worsen adherence36. A shuttling hypothesis, according 
to which DFP binds iron and then redistributes it to 
DFO, has been proposed37,38, and co-administration of 
these two chelators with an additive effect, could be 
an optimal strategy.
Common adverse effects of DFP are presented in 
Table I. The most serious adverse effects associated 
with DFP are agranulocytosis and neutropenia, with 
an incidence of 0.2 and 2.8 per 100 patient-years, 
respectively39. Weekly blood counts are strongly 
recommended in patients taking DFP. In particular, 
patients with bone marrow failure syndromes such as 
Diamond-Blackfan anaemia may be at higher risk of 
developing neutropenia with DFP40.
Retrospective studies have demonstrated reduced 
cardiac morbidity and mortality32,41-43 and lower 
myocardial iron deposition13 among patients treated 
with DFP than among those treated with DFO. 
Furthermore, in a randomised clinical trial among 
patients with moderate cardiac siderosis and normal 
cardiac function, significantly greater improvements 
in cardiac T2* and left ventricular function were 
seen after treatment with DFP than after treatment 
with DFO44. In a large clinical observational study, 
treatment with DFP resulted in an improvement in 
cardiac T2* among patients with all degrees of cardiac 
iron loading45. 
The combination of DFO and DFP is currently 
the most effective means of reducing cardiac iron 
loading and should be started in patients with 
significant cardiac siderosis. The chelators can 
be alternated to provide continuous exposure to 
chelation; for example, DFO given every night and 
DFP during the day can provide 14-hour removal 
of LPI6. The chelators can also be given at the same 
time, considering the possibility of a drug interaction 
through a so-called shuttle mechanism in which iron is 
chelated rapidly by DFP at sites relatively unavailable 
to DFO and then donated to the more stable DFO 
molecules. There is experimental evidence of this 
effect in animal models of iron overload37, and this 
shuttling was recently shown to occur in the removal 
of non-transferrin bound iron from the plasma 
compartment of patients with thalassaemia major38. 
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In practice, sequential use of DFO and DFP is more 
commonly adopted46-50.
The superiority of this combination compared 
with DFO alone was demonstrated in a randomised, 
placebo-controlled trial of 65 patients with mild 
to moderate cardiac iron loading51. Subjects who 
received combination therapy had significantly 
greater improvements in cardiac T2* and left 
ventricular ejection fraction than those receiving 
DFO with placebo. Furthermore, in a single-arm 
trial of patients with severe myocardial siderosis 
and myocardial dysfunction, combined treatment 
with DFO and DFP was effective in significantly 
improving cardiac T2* and left ventricular ejection 
fraction, as well as reducing serum ferritin and liver 
iron concentration after 12 months of therapy52.
More recently, a multicentre, randomised, open-
label trial was designed to assess the effectiveness 
of long-term alternating sequential DFP-DFO versus 
DFP alone in patients with beta-thalassaemia53. DFP 
75 mg/kg for 4 days/week and DFO 50 mg/kg/day 
for 3 days/week was compared with DFP alone 75 
mg/kg for 7 days/week during a 5-year follow-up. A 
total of 213 thalassaemic patients were randomised 
and intention-to-treat analysis was performed. The 
decrease of serum ferritin level was statistically 
significantly greater in patients treated with the 
alternating sequential DFP-DFO patients than in those 
treated with DFP alone (P=0.005). Kaplan-Meier 
survival analysis for the two chelation treatments 
did not show statistically significant differences (log-
rank test, P=0.3145). Adverse events and costs were 
comparable between the groups. These findings were 
confirmed in a further 21-month follow-up. These 
data suggest that alternating sequential DFP-DFO 
treatment may be useful for some patients with beta-
thalassaemia who may not be able to receive other 
forms of chelation treatment.
Formal safety data on combined treatments are 
limited. In general, alternating regimes are less 
likely to be an issue for toxicity compared with 
regimes in which chelation is simultaneous or 
overlapping. A meta-analysis of the incidence of 
agranulocytosis in patients treated with combined 
regimes suggested that the risk may be increased 
several-fold compared with that in patients treated 
with DFP monotherapy, although the number 
of evaluable patients was small54. The increased 
incidence seemed to occur mostly in regimes in which 
the drugs were administered simultaneously.
Deferasirox (DFX; Exjade®; Novartis Pharma 
AG, Basel, Switzerland) is the most recent oral 
iron chelator. It was developed as a once-daily oral 
iron chelator through a rational drug development 
programme and represents a new class of tridentate 
iron chelators55. DFX is currently approved in many 
countries worldwide for the treatment of chronic iron 
overload due to blood transfusions in patients 2 years 
of age and older (EXJADE® [deferasirox]. http//www.
pharma.us.novartis.com/product/pi/odf/exjade.pdf). 
The efficacy and the safety of DFX have been 
evaluated in patients with beta-thalassaemia24 and in a 
wide range of patients with other underlying anaemias 
including myelodysplastic syndromes (MDS), sickle 
cell disease, aplastic anaemia, Diamond-Blackfan 
anaemia and various other rare anaemias30,47,55-61.
Iron chelation with DFX may be beneficial 
because of its once-daily formulation, supported by 
its plasma half-life of 11 to 19 hours30,56. There are 
now data on compliance with DFX which, in the 
Evaluation of Patients' Iron Chelation with Exjade 
(EPIC) study, was reported to be greater than 80%60.
Two DFX studies in patients with beta-thalassaemia 
and sickle cell disease evaluated actual patients' 
feedback in the form of patient-reported outcomes. 
Most patients were more satisfied with DFX and 
found it more convenient than DFO therapy. A recent 
study by the Thalassemia Clinical Research Network 
examined adherence in 79 patients on DFO and 
186 on DFX from 2007 to 2009. Adherence to both 
DFO and DFX was highest in children, followed by 
adolescents and older adults. Switching chelators 
resulted in increased adherence, regardless of the 
direction of the switch, although switching from DFO 
to DFX was more common. 
The most common adverse effects of DFX are 
reported in Table I. DFX is typically well tolerated, 
with adverse events generally being mild. Transient 
gastrointestinal events, including abdominal pain, 
nausea and vomiting, diarrhoea and constipation 
occur in approximately 15% of patients with 
thalassaemia24 and in higher numbers of patients with 
MDS. Gastrointestinal disturbances are, in fact, the 
most common side effects but can often be improved 
by changing the time of day of DFX administration. 
Blood Transfus 2012; 10: 411-22  DOI 10.2450/2012.0008-12
Update on iron chelation therapy
411-422_008-12.indd   415 01/10/2012   10.17.38
416
Skin rashes occur early in approximately 10% of 
patients and are usually transient24. There have been 
rare reports of fulminant hepatic failure, leading to 
the suggestion that liver function should be monitored 
every 2 weeks for 1 month after starting therapy with 
DFX and then monthly thereafter. The levels of serum 
creatinine increase in approximately one-third of 
patients within a few weeks of starting or increasing 
therapy, but rarely reach the abnormal range24. 
Kidney function needs, therefore, to be monitored 
monthly. Audiometric effects and lens opacity did 
not differ significantly from those in patients treated 
with DFO24, and no drug-related agranulocytosis was 
observed. Because of its poor solubility in water, 
DFX is administered as a suspension in fruit juice. 
Its metabolism is predominantly to iron-binding 
glucoronides in the liver; iron excretion is dose-
dependent and almost entirely faecal30,56.
The efficacy of DFX at a dose of 20-30 mg/kg/day 
was shown to be similar to that of DFO in reducing 
liver iron concentration and serum ferritin levels in a 
large randomised trial in patients with thalassaemia 
major24. The drug's ability to remove hepatic iron has 
been demonstrated in several additional studies57,61.
Deugnier et al. observed an improvement in liver 
pathology in iron-overloaded beta-thalassaemia 
patients treated with DFX for at least 3 years62. In 
this study, histological data from 219 patients who 
had biopsy samples taken at baseline and after at 
least 3 years of treatment with DFX. DFX reversed 
or stabilised liver fibrosis in 83% of the patients and 
this therapeutic effect was independent of a reduction 
in the concentration of liver iron or previous exposure 
to hepatitis C virus62.
In a trial of 101 patients with mild to severe cardiac 
iron loading treated with DFX, cardiac T2* improved 
significantly in both the groups with mild-to-moderate 
and severe iron loading over 2 years of treatment63. No 
significant improvement in left ventricular ejection 
fraction was observed, although the ejection fraction 
was normal at baseline63. In another study of 22 
patients with cardiac T2* <20 ms treated with DFX 
for 18 months, cardiac T2* worsened in 14 patients 
and no change in left ventricular ejection fraction was 
seen over the 18 months of treatment. 
The failure to respond was predicted by higher 
baseline liver iron concentration and ferritin levels17. 
DFX can also prevent cardiac iron accumulation, 
as shown by Pennell et al.16. In 78 patients with 
thalassaemia without evidence of cardiac iron 
loading, cardiac T2* did not worsen over 1 year of 
treatment and no subjects with normal cardiac T2* 
at baseline developed an abnormal value over the 
follow-up period. In contrast to the patients with low 
cardiac T2* values, a significant improvement in 
ejection fraction was observed in the group of patients 
with a normal cardiac T2* at baseline.
The combination of DFX and DFO has not been 
extensively studied. In a pilot study, patients with 
thalassaemia major and evidence of iron-related 
organ dysfunction were treated with DFX daily and 
DFO for 3-7 days/week64. Liver iron concentration 
improved significantly and no toxicity was observed. 
Unfortunately, the combination of DFO and DFX 
did not show additive or synergetic effects on 
iron excretion in an iron-overloaded gerbil model, 
suggesting that the two chelators compete for a 
common iron pool65. It is not clear whether the same 
happens in human beings, but sequential rather 
than combination therapy could be preferred if 
the two chelators compete for the same iron pool. 
Further research regarding the safety and efficacy of 
combined treatment with DFO and DFX is necessary 
before recommendations can be made for routine 
clinical practice. Likewise, the combination of DFX 
and DFP still needs to be studied.
The ability of DFX to reverse cardiac disease 
has not yet been investigated, because all the prior 
studies required normal heart function for inclusion. 
Reversal of heart failure with DFX was reported in 
one patient with beta-thalassaemia and transfusional 
iron overload66. Further studies are needed to better 
delineate the effect of DFX on cardiac iron overload 
and iron-related cardiac dysfunction.
In the last year the level of "acceptable" iron 
burden in chronically transfused patients has been 
called into question67 and more "aggressive" chelation 
regimens have been advocated. Comparing the 
efficacy of the three chelators in suppressing LPI, 
it can be seen that a limitation of both DFO and 
DFP monotherapy is their inability to control levels 
of LPI constantly as a result of their short plasma 
half-lives68,69. In addition monotherapy may not be 
effective in all patients for a large variety of reasons. 
For example, adverse effects may prevent optimal 
dosing, while poor adherence to treatment may lead 
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to underdosing. Combination therapy may be more 
effective in these contexts.
DFO/DFP sequential therapy provides more 
consistent suppression of LPI than monotherapy with 
either chelator70 and is accompanied by a subsequent 
reduction in the frequency and dose of DFO reducing 
the risk of chelator toxicity. Recently, the combination 
of high doses of DFO (20-60 mg/kg/day) and DFP 
(75-100 mg/kg/day) led to normalisation of total body 
iron load in thalassaemia patients71. Furthermore, 
cardiac and endocrine complications, including 
hypothyroidism, hypogonadism and non-insulin-
dependent glucose intolerance, were reversed in 
some, but not all, patients treated with this regimen71. 
As DFX is detectable in the blood within the 
therapeutic range over a 24-hour period, it offers 
complete chelation coverage with standard dosing 
and can provide a sustained reduction in LPI72. The 
first prospective study to report long-term monitoring 
of the efficacy and safety of iron chelation with 
DFX in both paediatric and adult patients with beta-
thalassaemia suggests that treatment is generally 
well tolerated and effectively reduces iron burden73. 
Many patients achieved maintenance serum ferritin 
levels of ∼1,000 ng/mL, and treatment for ≤5 years 
was well tolerated. The study also provided the first 
data on the long-term effects on paediatric growth 
and adolescent sexual development for any oral iron 
chelation therapy. DFX did not show an adverse 
effect on paediatric growth or adolescent sexual 
development in paediatric patients who are prone to 
growth retardation as a result of iron overload73. These 
data confirm the results obtained in the published 
shorter-term clinical trials of 1-year duration60,61.
Iron chelation therapy in clinical practice
There are substantial data demonstrating the 
efficacy and safety of iron chelation therapy in the 
treatment of iron overload in regularly transfused 
patients with beta-thalassaemia8,57,60. The blood 
transfusion rate influences the chelator dose and 
careful monitoring of transfusional iron intake is 
needed, especially in young children, in order to avoid 
exceeding the therapeutic index of the chelator and, as 
a consequence, increasing the risk of adverse effects.
Data supporting the use of iron chelation therapy 
in other transfusion-dependent anaemias such as 
MDS, aplastic anaemia and sickle cell disease are also 
accumulating57,58,60,74,75 and suggest that the response in 
terms of iron balance is mainly dependent on chelator 
dose and transfusional iron loading rate57,58,60,74-76.
Studies in patients affected by rare anaemias 
related to decreased RBC production, including 
Diamond-Blackfan anaemia and pure red cell 
aplasia, as well as those in patients with haemolytic 
anaemia have been limited57, and response has 
not been analysed with respect to the underlying 
mechanism of anaemia.  However, the 1-year EPIC 
study enrolled a large number of patients with 
different types of transfusion-dependent anaemia60, 
thereby enabling the investigation of disease-specific 
factors that might affect iron chelation therapy with 
DFX. A subsequent study, including patients with 
rare transfusion-dependent anaemias from the EPIC 
study, examined how responses of these rare blood 
disorders to DFX chelation were affected by the 
underlying mechanism of the anaemia (decreased 
RBC production or haemolysis)77. The efficacy 
and safety of DFX were evaluated over 1 year, 
with the change in serum ferritin concentration 
being the primary efficacy end-point. Transfusional 
iron-loading rates, mean DFX dosing and baseline 
median serum ferritin levels were comparable 
in patients with anaemia due to either decreased 
RBC production or haemolysis. In both cohorts the 
responses to DFX were similar at 1 year, irrespective 
of the underlying pathogenic mechanism necessitating 
the chronic blood transfusions77. These data provide 
evidence that transfusional iron overload in patients 
with a variety of rare anaemias may be effectively 
managed using a tailored DFX dosing regimen, 
based on individual blood transfusion requirements, 
regular monitoring of serum ferritin trends and safety 
parameters77.
The efficacy of iron chelation on survival in 
patients with MDS is still a matter of discussion 
because of the lack of randomised trials with a 
survival end-point, although evidence suggests that 
improvements in survival are likely78-81. In the EPIC 
study, 341 patients with MDS were treated with DFX, 
obtaining a significant decrease in the overall median 
serum ferritin levels after 1 year of treatment82. 
Recently, data from patients with MDS showed 
that DFX can improve haematological parameters, 
including haemoglobin concentration, transfusion 
requirements and neutrophil and platelet counts83-86. 
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Survival data for patients with MDS treated with DFX 
are lacking; a randomised, double-blind, placebo-
controlled phase III trial (TELESTO) comparing DFX 
to placebo is currently underway.
The benefits of reduced iron levels in bone marrow 
transplant patients, before and after transplantation, 
have been recognised and DFX could have a potential 
role in the treatment of iron load in this population of 
patients. Iron overload has been reported in adults after 
haematopoietic stem cell transplantation (HSCT)87,88 
and could be a significant contributor to treatment-
related mortality in patients with haematological 
malignancies undergoing HSCT. It is well known 
that iron overload is an important adverse prognostic 
factor for patients with thalassaemia undergoing 
HSCT89,90. This may also hold true for patients 
who undergo transplantation for haematological 
malignancies91. Recent studies have suggested a link 
between iron overload and post-transplantation liver 
toxicity (including chronic liver disease and veno-
occlusive disease)92, susceptibility to infections93, and 
veno-occlusive disease94.
Although iron overload both before and after 
transplantation and its effects on end organ toxicity 
are legitimate concerns in high-risk MDS, many 
questions remain unresolved with regards to the 
potential role of iron chelation therapy in this context. 
Prospective studies incorporating T2* MRI of the 
heart and iron as well as alternative biomarkers of iron 
stores are needed to improve our understanding of 
the extent as well as the temporal significance of iron 
overload in patients undergoing allogeneic HSCT. 
The studies should also address the relationship 
between pre-transplant transfusions and iron overload 
within each haematological disease group. Given 
the absolute difference in 5 year-overall survival for 
patients with MDS between those with the highest 
and lowest ferritin quartiles95, judicious chelation 
therapy could lead to a significant improvement in 
transplantation outcomes for these patients.
Iron chelation therapy is currently focused on the 
treatment of patients with transfusional iron overload; 
however, a wider prospective is being taken with the 
use of DFX being investigated in a number of other 
conditions including hereditary haemochromatosis, 
characterised by progressive iron loading through 
increased intestinal iron absorption96; porphyria 
cutanea tarda, a common type of porphyria which 
can be associated with haemochromatosis97; and 
mucormycosis98.
Finally, studies have demonstrated that iron is 
a crucial element for the proliferation of tumour 
cells, and as a consequence, the potential role of 
iron chelation in the treatment of cancer must be 
considered in the near future99.
Conclusion
Long-term RBC transfusion therapy is required 
for the treatment of several types of congenital and 
acquired anaemia, such as thalassaemia syndromes, 
sickle cell disease, MDS, Diamond-Blackfan anaemia 
and aplastic anaemia. Chronic blood transfusions 
inevitably lead to iron overload and serious clinical 
sequelae and patients receiving such transfusions, 
therefore, requires lifelong chelation therapy. Several 
factors, including the availability of a given chelator 
and its properties, drug tolerability, transfusional 
iron burden and the patient's compliance must be 
considered in the design of optimal, individualised 
chelation regimens, and all these factors must 
regularly be reviewed and the chelation modified 
accordingly. Adherence to DFO is generally poor and 
a patient's attitude to adherence can change over time. 
The availability of oral iron chelators, such as DFP 
and DFX, may contribute to improved compliance, 
especially among paediatric and adolescent patients 
in whom compliance is a particular issue. Adherence 
may also be improved by offering patients greater 
choice in chelation.
The challenging task for the future is to design a 
chelator that: (i) is orally active; (ii) can cross cell 
membranes; and (iii) is capable of scavenging iron 
from specific areas of the body, such as the heart, the 
liver, the endocrine glands and the brain, sparing the 
bulk of physiologically essential iron. 
A number of oral iron chelators are currently under 
development, including an α-ketohydroxypyridine 
analogue of DFP, LINAII, and a novel oral once-daily 
iron chelator, FBS0701100. 
In a multicentre phase 2 study of the safety, 
tolerability and pharmacodynamics of FBS070I, 51 
adult patients, stratified by transfusional iron intake, 
were randomised to FBS0701 at a dose of 14.5 or 29 
mg/kg/day (16 and 32 mg/kg/day of the salt form)101. 
FBS0701 was generally well tolerated at both doses. 
Forty-nine patients (96%) completed the study. There 
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were no drug-related serious adverse events. No 
adverse events showed dose-dependency in frequency 
or severity. Treatment-related nausea, vomiting, 
abdominal pain, and diarrhea were each noted in 
<5% of patients. The most common treatment-
related adverse event was increased transaminases 
(16%, N=8). Three of these eight patients acquired 
a hepatitis C virus infection on-study from a single 
blood bank; the five others had abnormal baseline 
alanine transaminase. Mean serum creatinine did 
not change significantly from baseline or differ 
between dose groups. The change in 24-week liver 
iron concentration (ΔLIC) differed according to the 
dose of FBS0701: the mean ΔLIC for patients treated 
with 14.5 mg/kg/day was +3.1 mg/g (dry weight); 
29% achieved a decrease in LIC. The mean ΔLIC 
among the patients treated with 29 mg/kg/day was 
–0.3 mg/g (dry weight) and 44% achieved a decrease 
in LIC (P<0.03 for ΔLIC between doses). The safety 
and tolerability profile at therapeutic doses compare 
favourably with those of other oral chelators101.
Finally, the development of more sensitive 
methods for quantifying iron could improve treatment 
and monitoring of therapeutic efficacy in iron 
overload disorder s. 
Keywords: iron overload, chelation therapy, 
transfusion-dependent disorders, thalassaemia, iron.
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